ImpriMed
Seoul-based precision medicine company that combines lab testing of patient-derived cancer cells with multimodal AI for treatment decisions.
- Industry
- precision medicine, oncology, healthcare AI
- Location
- Seoul, South Korea
About
ImpriMed's xCellSense platform keeps patient cancer cells viable outside the body so clinicians can test drug responses alongside genomic and clinical data. The company is expanding from veterinary oncology into human healthcare commercialization.
Funding history
| Round | Date | Amount | Lead |
|---|---|---|---|
| Series A2 2026 | 2026-09-21 | $10M | LB Investment |
Investors
- LB Investment lead
- NAVER D2SF participant
- Samsung Securities participant
- Alois Ventures participant
- BonAngels participant
- Han River Partners participant
Sources
Last verified:
- https://www.finsmes.com/2026/09/imprimed-raises-10m-in-series-a2-bridge-funding.html
Type: reputable publication. Accessed 2026-10-07.
FinSMEs article dated 2026-09-21. Reports a $10 million Series A2 bridge led by LB Investment with NAVER D2SF, Samsung Securities, Alois Ventures, BonAngels and Han River Partners, and a Seoul location. - https://www.citybiz.co/article/905872/naver-d2sf-invests-in-imprimeds-10-million-precision-medicine-round/
Type: reputable publication. Accessed 2026-10-07.
Citybiz article. Confirms NAVER D2SF joined the $10 million Series A2 bridge led by LB Investment with Samsung Securities, Alois Ventures, BonAngels and Han River Partners.